An apparatus includes a first member coupled to a second member. The first member defines a chamber containing a dry powder and includes a chamber wall that forms an outer boundary of the chamber. The second member includes a surface covering the chamber and defines an intake channel and an exit channel. The exit channel is fluidically coupled to the chamber via an exit opening. The intake channel is fluidically coupled to the chamber via an intake port. A center line of the intake channel is tangential to a portion of the chamber wall such that a portion of an inlet airflow conveyed into the chamber via the intake channel has a rotational motion. The intake port is defined at least in part by an intake ramp. The intake ramp includes a transition surface that forms an exit angle with respect to the surface of less than 105 degrees.

An example aerosol delivery device includes a mouthpiece having an airflow outlet, and an airflow passage extending between an airflow inlet and the airflow outlet. The example aerosol delivery device further includes a housing configured to receive a cartridge that includes an aerosolizable substance and a vapor element configured to heat the aerosolizable substance, and an internal power source configured to provide electrical power. The example aerosol delivery device further includes a controller coupled to the internal power source to receive a portion of the electrical power and configured to, when the cartridge is installed at the housing, cause the vapor element of the cartridge to heat the aerosolizable substance to release an aerosol into the airflow passage during an inhalation through the airflow outlet, and a connector configured to receive power from an external source to recharge the internal power source.

An inhaler or add-on device for an inhaler for dispensing a medicament to be inhaled. The inhaler or add-on device has a housing (H) with an air inlet (A_I), and an air outlet (A_O) for outputting air to be inhaled by a user. The housing (H) defines a flow path (FP) between the air inlet (A_I) and air outlet (A_O), and a passive acoustic element (PAE) is arranged in this flow path (FP) inside the housing (H). The passive acoustic element (PAE) has a structure having one or more structured gaps arranged to be passed by an air flow and it is dimensioned such that air flow passing it will generate sound (S) with pre-determined characteristics depending on the air flow speed. This allows acoustic monitoring of air flow passing the first passive acoustic element (PAE) external to the housing (H) by capturing and processing sound generated.

The present disclosure relates to a mouthpiece (40) for delivering an aerosol supplied by a nebulizer (100) to a user, the mouthpiece (40) comprising a body (46) defining a fluid path (47) from an inlet port (41) connectable to the nebulizer (100) to an inhalation opening (42) to be received in the mouth of a user and a filter (30). The filter (30) has a filter base (31) in fluid communication with the fluid path (47), a filter top (33) detachably connected to the filter base (31) and a filter material (32) provided between the filter base (31) and the filter top (33). The filter top (33) has an exhalation opening (36) cooperating with a one-way valve (39) allowing exhaustion of fluid from the fluid path (47) through the filter material (32) to the outside of the mouthpiece upon exhalation of a patient through the inhalation opening (42). The body (46) and the filter base (31) are an integrated one-piece unit so as to provide for an easy to handle and comfortable mouthpiece (40).

The present invention relates to an inhalation chamber including a body having an inlet orifice suitable for being connected to the outlet end piece of a metered dose inhaler and an outlet orifice suitable for being connected to a mouthpiece or a mask to apply on the face of a patient, and a support suitable for receiving the outlet end piece of the metered dose inhaler, the support opening into the inlet orifice, characterised in that the axis (X) of the inlet orifice is non-colinear with the axis (Y) of the outlet orifice and in that the support is pivotally mounted on the body around the axis (X) of the inlet orifice.

Containment units, dry powder inhalers, delivery systems, and methods for the same are disclosed. Exemplary devices are configured to have inlets and outlets which are formed with the containment walls of a containment unit. Air jets formed by the configuration of inlet(s) and outlet(s) inside the containment unit create significant turbulence and deaggregate the powder. Delivery system components downstream of the containment unit may integrate the exiting aerosol plume with a low flow nasal cannula air stream for delivery to a subject.

A dry salt therapy device includes a blower, an exhaust passage fluidly coupled to the blower, a grinding chamber configured to aerosolize salt, and a salt vent fluidly coupling the exhaust passage and the grinding chamber. A flow structure may be provided. The grinding chamber may have a particular aspect ratio, tip clearance, or floor clearance. Salt may be delivered to a user without contacting the user, the salt being delivered in a jet having a particular diameter at a particular distance. The device can include a converging-diverging nozzle in the exhaust passage. The salt vent may protrude into a center of a flow of air through the exhaust passage.

A dry powder inhaler for pulmonary or nasal use, comprising at least an inhaler body (201) and a cartridge (203) with a plurality of powder compartments (205) each including one dose of a drug. The body (201) has an opening (204) shaped for receiving the cartridge (203) and the plastic body recess (215) and the detent (218) to allow a controlled advancement and turning movement of the cartridge (203) relative to the body (201) for sequentially delivering each of the plurality of unit doses filled into the cartridge compartments (205). The inhaler construction is suitable for filling the plurality of unit doses into the compartments (205) with the cartridge (203) assembled into the body (201). The invention affords a large dose inhaler of single-use and low cost that improves industrial filling and manufacturing cost for the delivery of high dosages of inhaled medicines.

An apparatus includes a first member coupled to a second member. The first member defines a chamber containing a dry powder and includes a chamber wall that forms an outer boundary of the chamber. The second member includes a surface covering the chamber and defines an intake channel and an exit channel. The exit channel is fluidically coupled to the chamber via an exit opening. The intake channel is fluidically coupled to the chamber via an intake port. A center line of the intake channel is tangential to a portion of the chamber wall such that a portion of an inlet airflow conveyed into the chamber via the intake channel has a rotational motion. The intake port is defined at least in part by an intake ramp. The intake ramp includes a transition surface that forms an exit angle with respect to the surface of less than 105 degrees.

The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.